KIR2DL1/KIR2DS5 Antibody (Innate patent anti-KIR2DL) [DyLight 650]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28027C
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 650 (Excitation = 652 nm, Emission = 672 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Innate patent anti-KIR2DL
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
KIR2DL1 / CD158a
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for KIR2DL1/KIR2DS5 Antibody (Innate patent anti-KIR2DL) [DyLight 650]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: KIR2DL1/KIR2DS5
Alternate Names
CD158a
Gene Symbol
KIR2DL1
Additional KIR2DL1/KIR2DS5 Products
Product Documents for KIR2DL1/KIR2DS5 Antibody (Innate patent anti-KIR2DL) [DyLight 650]
Product Specific Notices for KIR2DL1/KIR2DS5 Antibody (Innate patent anti-KIR2DL) [DyLight 650]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...